We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Circulating Tumor DNA as a Complementary Prognostic Biomarker during CAR-T Therapy in B-Cell Non-Hodgkin Lymphomas.
- Authors
Monick, Sarah; Rosenthal, Allison
- Abstract
Simple Summary: Circulating tumor DNA (ctDNA) is an emerging, multifaceted biomarker for predicting outcomes in B-cell non-Hodgkin lymphomas (B-NHL) following CD19-directed CAR-T therapy. Conventional imaging techniques face challenges in accurately assessing treatment response and detecting early relapse, highlighting the need for non-invasive analytes like ctDNA. By overcoming these limitations, ctDNA offers real-time insights into treatment response, resistance mechanisms, and early relapse detection. Integration of ctDNA monitoring into clinical practice has the potential to personalize therapeutic strategies, optimize patient outcomes, and guide the development of novel therapeutics. However, standardization of assay methods and consensus on clinical response metrics are essential for realizing its full potential in relapsed/refractory (R/R) B-NHL management. The emergence of CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the treatment paradigm for R/R B-cell NHLs. However, challenges persist in accurately evaluating treatment response and detecting early relapse, necessitating the exploration of novel biomarkers. Circulating tumor DNA (ctDNA) via liquid biopsy is a non-invasive tool for monitoring therapy efficacy and predicting treatment outcomes in B-NHL following CAR-T therapy. By overcoming the limitations of conventional imaging modalities, ctDNA assessments offer valuable insights into response dynamics, molecular mechanisms of resistance, and early detection of molecular relapse. Integration of ctDNA monitoring into clinical practice holds promise for personalized therapeutic strategies, guiding the development of novel targeted therapies, and enhancing patient outcomes. However, standardization of assay methodologies and consensus on clinical response metrics are imperative to unlock the full potential of ctDNA in the management of B-NHL. Prospective validation of ctDNA in clinical trials is necessary to establish its role as a complementary decision aid.
- Subjects
IMMUNIZATION; NON-Hodgkin's lymphoma; EARLY detection of cancer; TUMOR markers; TREATMENT effectiveness; BODY fluid examination; NUCLEIC acids; EXTRACELLULAR space; CARCINOGENESIS
- Publication
Cancers, 2024, Vol 16, Issue 10, p1881
- ISSN
2072-6694
- Publication type
Article
- DOI
10.3390/cancers16101881